Stocks
Coherus Oncology, Inc.CHRS
NASDAQHealthcareBiotechnology$1.63-3.55%
Specializing in immuno-oncology, the company develops and commercializes therapies aimed at treating cancer through innovative biologics. Its flagship products include biosimilars and proprietary drugs targeting immune checkpoint inhibitors, making it a key player in the oncology market. Investors monitor its pipeline advancements and regulatory milestones closely.
Market Cap: $190.9M52W Range: $0.71 – $2.62
Congressional Interest in Coherus Oncology, Inc. (CHRS)
1 member of Congress has disclosed 1 trade in Coherus Oncology, Inc. (CHRS), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading CHRS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-23 | Shri Thanedar | sell | $15K – $50K |